$CMPR

Cimpress (NASDAQ: CMPR) CEO exercises PSUs and covers tax with shares

Cimpress CEO Robert S. Keane reported equity compensation activity, with 13,112 ordinary shares vesting from performance share units (PSUs) on May 15, 2026. To cover tax obligations, 4,522 shares were disposed of at $93.25 each in a non-market transaction. Following these actions, Keane directly holds 82,677 ordinary shares, with substantial indirect holdings also reported through various LLCs and an investment trust.

Original reporting
Published May 19, 2026, 3:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 19, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CMPR
Neutral
medium confidence
Mentioned
$CMPR · $CMPR
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$CMPRNeutralLow
01

Why it matters

This activity is unlikely to impact the company's operational outlook but may influence short-term stock price due to perceived insider confidence or liquidity needs.

02

Market read

The news is relevant to investors monitoring insider activities and executive compensation impacts on stock performance.

03

What to watch

The insider sold shares to cover taxes, a common event not necessarily linked to company performance; broader market conditions and company fundamentals should be considered.

Relevance 6/10Timing: short-term (within days to weeks)

Background

Cimpress's CEO exercised performance share units (PSUs) and disposed of shares to cover tax obligations, a routine part of executive compensation management.

Company-level read

Ticker impact

$CMPRNeutralMedium confidence
Context

The news pertains directly to Cimpress (NASDAQ: CMPR), involving insider activity by the CEO, which may influence investor perception and stock price.

Expected impact

Potential short-term volatility with a slight upward bias due to insider confidence; long-term impact remains uncertain.

Evidence & confidence

The insider activity is routine but noteworthy; market reaction depends on broader context and investor interpretation.

$CMPRNeutralMedium confidence
Context

The news is highly relevant to Cimpress shareholders and potential investors, given the insider transactions and holdings update.

Expected impact

Minimal immediate impact; possible slight downward pressure if market interprets insider selling negatively.

Evidence & confidence

The activity is routine and does not necessarily reflect company performance or outlook.

Market effects

Limited; the activity is specific to company insiders and does not indicate sector-wide changes.

Minimal; no regional effects expected.

Negligible; the news is company-specific.

Counterpoint

Some investors may interpret insider selling as a sign of upcoming challenges or profit-taking, potentially leading to short-term price declines.

Key entities

  • Robert S. Keane

    CEO of Cimpress who exercised PSUs and sold shares.

  • Cimpress plc

    The company involved in the insider activity.

Related articles

$CMPRLow

CIMPRESS plc (CMPR): Results of Operations and Financial Condition

CIMPRESS plc (CMPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. cmpr-20260729 0001262976 false 0001262976 2024-10-30 2024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date o

$CMPRMedAI 8/10

Cimpress (NASDAQ:CMPR) Reaches New 52

Cimpress plc (NASDAQ:CMPR) hit a new 52-week high on Tuesday, trading up to $105.00 and last at $104.94 versus a prior close of $102.39. The article also cites recent analyst actions: Zacks downgraded to “hold,” while Truist set a $110 target and Barrington raised its to $113. On April 29, Cimpress reported Q1 EPS of $0.55 and revenue of $886.21M.

$NVDAMed

Nvidia's AI Financing Faces First Big Market Test

Nvidia is financing AI projects, offering $500B in off-balance-sheet guarantees. CEO Jensen Huang aims to fund demand, citing strong interest. Nvidia's revenue hit $216B in FY2024, with $70B in free cash flow. Partners like CoreWeave face credit tightening, with shares down 30%. Nvidia's stock fell 7.6% in October, raising concerns about demand meeting expectations.

$AZNHigh

AZ Combo Extends Lung Cancer Survival

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.

$MRNAHigh

New Personalised mRNA Therapy Improves Melanoma Outcomes: ESMO 2026

A Phase III trial showed that intismeran autogene, a personalized mRNA therapy, combined with pembrolizumab, reduced the risk of death or recurrence by 42% in high-risk melanoma patients. The study, presented at ESMO 2026, enrolled 1,137 patients and demonstrated improved recurrence-free and distant metastasis-free survival. Despite the positive clinical results, a data leak caused shares of manufacturers Moderna and Merck to fall.